AbbVie Announces Data from Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress

North Chicago, Ill., (STL.News) – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZIâ„¢ (risankizumab) at 2.5…

The post AbbVie Announces Data from Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress appeared first on STL.News.